Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ACYCLOVIR Cause Product use in unapproved indication? 387 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 387 reports of Product use in unapproved indication have been filed in association with ACYCLOVIR (Acyclovir). This represents 2.7% of all adverse event reports for ACYCLOVIR.

387
Reports of Product use in unapproved indication with ACYCLOVIR
2.7%
of all ACYCLOVIR reports
96
Deaths
142
Hospitalizations

How Dangerous Is Product use in unapproved indication From ACYCLOVIR?

Of the 387 reports, 96 (24.8%) resulted in death, 142 (36.7%) required hospitalization, and 41 (10.6%) were considered life-threatening.

Is Product use in unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ACYCLOVIR. However, 387 reports have been filed with the FAERS database.

What Other Side Effects Does ACYCLOVIR Cause?

Drug ineffective (1,727) Acute kidney injury (1,405) Off label use (942) Headache (694) Condition aggravated (584) Pyrexia (565) Nausea (537) Rash (461) Neurotoxicity (460) Dyspnoea (446)

What Other Drugs Cause Product use in unapproved indication?

DUPILUMAB (33,452) DICLOFENAC (12,197) METHOTREXATE (8,930) PREDNISONE (7,625) RITUXIMAB (7,519) MYCOPHENOLATE MOFETIL (5,910) ACETAMINOPHEN (5,819) CYCLOPHOSPHAMIDE (5,750) RISPERIDONE (5,551) TACROLIMUS (5,057)

Which ACYCLOVIR Alternatives Have Lower Product use in unapproved indication Risk?

ACYCLOVIR vs AD26.COV2.S ACYCLOVIR vs ADAGRASIB ACYCLOVIR vs ADALIMUMAB ACYCLOVIR vs ADALIMUMAB-AACF ACYCLOVIR vs ADALIMUMAB-AATY

Related Pages

ACYCLOVIR Full Profile All Product use in unapproved indication Reports All Drugs Causing Product use in unapproved indication ACYCLOVIR Demographics